Schedule 1 – Relevant Services

<table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><thead><tr><td colspan="4" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Group P2—Chemical</span></p></td></tr><tr><td style="width:16.22%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Item</span></p></td><td style="width:63.18%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Description</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:29.7pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Fee ($)</span></p></td></tr></thead><tbody><tr><td style="width:16.22%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>66520</span></p></td><td style="width:63.18%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-bottom:12pt"><span>Fibroblast growth factor 23 quantification in serum or plasma, requested by a specialist or consultant physician to determine eligibility for a relevant treatment listed on the Pharmaceutical Benefits Scheme</span></p></td><td style="width:20.52%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-left:1pt; text-align:right"><span>90.00</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:top"></td></tr><tr style="height:0pt"><td style="width:69.15pt"></td><td style="width:269.35pt"></td><td style="width:87.5pt"></td><td style="width:0.35pt"></td></tr></tbody></table>

<table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><thead><tr><td colspan="4" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Group P5—Tissue pathology</span></p></td></tr><tr><td style="width:16.22%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Item</span></p></td><td style="width:63.18%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Description</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:29.7pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Fee ($)</span></p></td></tr></thead><tbody><tr><td style="width:16.22%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>72814</span></p></td><td style="width:63.18%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><a id="_Hlk145140237"><span>Immunohistochemical examination by immunoperoxidase or other labelled antibody techniques using the programmed cell death ligand 1 (PD‑L1) antibody of tumour material from a patient diagnosed with:</span></a></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(a)</span><span style="width:5.59pt; text-indent:0pt; display:inline-block"> </span><span>non‑small cell lung cancer; or</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(b)</span><span style="width:4.97pt; text-indent:0pt; display:inline-block"> </span><span>recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx; or</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(c)</span><span style="width:5.59pt; text-indent:0pt; display:inline-block"> </span><span>locally recurrent unresectable or metastatic triple</span><span>‑</span><span>negative breast cancer.</span></p></td><td style="width:20.52%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-left:1pt; text-align:right"><span>76.30</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:top"></td></tr><tr style="height:0pt"><td style="width:69.15pt"></td><td style="width:269.35pt"></td><td style="width:87.5pt"></td><td style="width:0.35pt"></td></tr></tbody></table>

<table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><thead><tr><td colspan="3" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Group P7—Genetics</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Item</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Description</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:47.85pt; page-break-after:avoid; line-height:12pt"><span style="font-weight:bold">Fee ($)</span></p></td></tr></thead><tbody><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73295</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><a id="_Hlk183067664"><span>Detection of germline </span><span style="font-style:italic">BRCA1</span><span> or </span><span style="font-style:italic">BRCA2</span><span> pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with:</span></a></p><p class="Item" style="margin-left:17.85pt; text-indent:-17.85pt"><span>(a)</span><span style="width:5.64pt; text-indent:0pt; display:inline-block"> </span><span>advanced (FIGO III</span><span>‑</span><span>IV) high</span><span>‑</span><span>grade serous or high</span><span>‑</span><span>grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or</span></p><p class="Item" style="margin-left:17.85pt; text-indent:-17.85pt"><span>(b)</span><span style="width:5.02pt; text-indent:0pt; display:inline-block"> </span><span>breast cancer.</span></p><p style="margin-top:14pt; margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Applicable once per lifetime</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>1,200.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73301</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>A test of tumour tissue from a patient with advanced (FIGO III</span><span>‑</span><span>IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to</span><span> </span><span style="font-style:italic">BRCA</span><span> </span><span>status for access to treatment with a poly (adenosine diphosphate [ADP]</span><span>‑</span><span>ribose) polymerase (PARP) inhibitor under the</span><span> </span><span>Pharmaceutical Benefits Scheme (PBS)</span></p><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Applicable</span><span> </span><span>once per primary tumour diagnosis</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>1,200.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73302</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Characterisation of germline gene variants including copy number variants, in </span><span style="font-style:italic">BRCA1</span><span> or </span><span style="font-style:italic">BRCA2</span><span> genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items</span><span> </span><span>73295, 73296 or 73297 applies, requested by a specialist or consultant physician</span></p><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Applicable once per primary tumour diagnosis</span></p><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Note: Items</span><span> </span><span>73296 and 73297 are in the pathology services table.</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>400.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>73303</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>A test of tumour tissue from a patient with metastatic castration</span><span>‑</span><span>resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to </span><span style="font-style:italic">BRCA</span><span> status for access to a relevant treatment under the Pharmaceutical Benefits Scheme;</span></p><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Applicable once per primary tumour diagnosis</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-left:8.85pt; text-align:right; page-break-after:avoid"><span>1,000.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>73304</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Detection of germline </span><span style="font-style:italic">BRCA1</span><span> or </span><span style="font-style:italic">BRCA2</span><span> pathogenic or likely pathogenic gene variants, in a patient with metastatic castration</span><span>‑</span><span>resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme;</span></p><p style="margin-bottom:6pt; line-height:normal; background-color:#ffffff"><span>Applicable once per lifetime</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-left:8.85pt; text-align:right; page-break-after:avoid"><span>1,000.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>73307</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>A test of tumour tissue from a patient with advanced (FIGO III</span><span>‑</span><span>IV), high</span><span>‑</span><span>grade serous or other high</span><span>‑</span><span>grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is:</span></p><p class="Item" style="margin-left:17.85pt; text-indent:-17.85pt"><span>(a)</span><span style="width:5.64pt; text-indent:0pt; display:inline-block"> </span><span>to determine eligibility with respect to homologous recombination deficiency (HRD) status, including </span><span style="font-style:italic">BRCA1 </span><span>or</span><span style="font-style:italic"> BRCA2 </span><span>status, to provide access to poly (adenosine diphosphate [ADP]</span><span>‑</span><span>ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(b)</span><span style="width:4.97pt; text-indent:0pt; display:inline-block"> </span><span>including a service described in item 73301</span></p><p style="margin-top:6pt; margin-bottom:6pt"><span style="vertical-align:-3pt">Applicable once per primary tumour diagnosis</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="text-align:right"><span>3,000.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>73319</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme.</span></p><p><span></span></p><p><span>Applicable only once per lifetime</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="text-align:right"><span>340.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73332</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="line-height:12pt; background-color:#ffffff"><span>An in situ hybridisation (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme or the Herceptin Program are fulfilled.</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>315.40</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73336</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="line-height:12pt; background-color:#ffffff"><span>A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>230.95</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73337</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>A test of tumour tissue from a patient with a new diagnosis of non</span><span>‑</span><span>small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is:</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(a)</span><span style="width:5.59pt; text-indent:0pt; display:inline-block"> </span><span>for epidermal growth factor receptor (EGFR) status to determine eligibility for a</span><span style="font-style:italic"> </span><span>relevant treatment under the Pharmaceutical Benefits Scheme; and</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(b)</span><span style="width:4.97pt; text-indent:0pt; display:inline-block"> </span><span>not associated with a service to which item 73437 or 73438 applies</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>397.35</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73338</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:6pt; line-height:12pt; background-color:#ffffff"><span>A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if:</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(a)</span><span style="width:5.59pt; text-indent:0pt; display:inline-block"> </span><span>requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if:</span></p><p class="Item" style="margin-left:34.9pt; text-indent:-17.8pt"><span>(i)</span><span style="width:7.42pt; text-indent:0pt; display:inline-block"> </span><span>the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or</span></p><p class="Item" style="margin-left:34.9pt; text-indent:-17.8pt"><span>(ii)</span><span style="width:4.36pt; text-indent:0pt; display:inline-block"> </span><span>a clinically</span><span>‑</span><span>relevant RAS variant is detected;</span></p><p style="margin-top:6pt; margin-left:17.8pt; line-height:12pt; background-color:#ffffff"><span>and, in cases where no RAS variant is detected:</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(b)</span><span style="width:4.97pt; text-indent:0pt; display:inline-block"> </span><span>the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>362.60</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73341</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is:</span></p><p class="Item" style="margin-left:17.1pt; text-indent:-17.1pt"><span>(a)</span><span style="width:4.89pt; text-indent:0pt; display:inline-block"> </span><span>for ALK gene rearrangement status to determine eligibility for a</span><span style="font-style:italic"> </span><span>relevant treatment under the Pharmaceutical Benefits Scheme; and</span></p><p class="Item" style="margin-left:17.1pt; text-indent:-17.1pt"><span>(b)</span><span style="width:4.27pt; text-indent:0pt; display:inline-block"> </span><span>not associated with a service to which item 73437 or 73439 applies</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>400.00</span></p></td></tr><tr><td style="width:15.38%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73342</span></p></td><td style="width:64%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="line-height:12pt; background-color:#ffffff"><span>An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro</span><span>‑</span><span>oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.</span></p></td><td style="width:20.62%; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>315.40</span></p></td></tr><tr><td style="width:15.38%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73344</span></p></td><td style="width:64%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p><span>Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is:</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(a)</span><span style="width:5.59pt; text-indent:0pt; display:inline-block"> </span><span>for ROS1 gene arrangement status to determine eligibility for a</span><span style="font-style:italic"> </span><span>relevant treatment under the Pharmaceutical Benefits Scheme; and</span></p><p class="Item" style="margin-left:17.8pt; text-indent:-17.8pt"><span>(b)</span><span style="width:4.97pt; text-indent:0pt; display:inline-block"> </span><span>not associated with a service to which item 73437 or 73439 applies</span></p></td><td style="width:20.62%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>400.00</span></p></td></tr><tr><td style="width:15.38%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73351</span></p></td><td style="width:64%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="line-height:12pt; background-color:#ffffff"><span>A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non</span><span>‑</span><span>small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to </span><span style="font-style:italic">EGFR</span><span> </span><span style="font-style:italic">T790M</span><span> gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled.</span></p></td><td style="width:20.62%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:8.85pt; margin-bottom:3pt; text-align:right; page-break-after:avoid; line-height:115%"><span>397.35</span></p></td></tr><tr style="height:1pt"><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>73430</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">Fluorescence in</span><span style="font-family:'Times New Roman', serif">‑</span><span style="font-family:'Times New Roman', serif">situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic solid tumour, if:</span></p><p class="Tabletext1" style="margin-left:24.95pt; margin-bottom:0pt; text-indent:-17.85pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(a)</span><span style="width:5.64pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">the tumour is at risk of being caused by a neurotrophic receptor tyrosine kinase (</span><span style="font-family:'Times New Roman', serif; font-style:italic">NTRK</span><span style="font-family:'Times New Roman', serif">) gene fusion as determined by either:</span></p><p class="Tabletext1" style="margin-left:53.9pt; margin-bottom:0pt; text-indent:-11.35pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(i)</span><span style="width:0.97pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">occurring in a child less than 18 years of age; or</span></p><p class="Tabletext1" style="margin-left:53.9pt; margin-bottom:0pt; text-indent:-11.35pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(ii)</span><span style="width:16.01pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">being mammary analogue secretory carcinoma of the salivary gland; or</span></p><p class="Tabletext1" style="margin-left:53.9pt; margin-bottom:6pt; text-indent:-11.35pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(iii)</span><span style="width:12.96pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">being secretory breast carcinoma; and</span></p><p class="Tabletext1" style="margin-left:25.1pt; margin-bottom:6pt; text-indent:-18pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(b)</span><span style="width:5.17pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">the test is requested by a specialist or consultant physician to determine if requirements relating to </span><span style="font-family:'Times New Roman', serif; font-style:italic">NTRK</span><span style="font-family:'Times New Roman', serif"> gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled</span></p><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">This item cannot be claimed if item</span><span style="font-family:'Times New Roman', serif"> </span><span style="font-family:'Times New Roman', serif">73433 has been claimed for the same patient during the same cancer diagnosis</span></p><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">Applicable only once per cancer diagnosis</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">400.00</span></p></td></tr><tr><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>73431</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">Two tests described in item</span><span style="font-family:'Times New Roman', serif"> </span><span style="font-family:'Times New Roman', serif">73430</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">533.00</span></p></td></tr><tr><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>73432</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">Three or more tests described in item</span><span style="font-family:'Times New Roman', serif"> </span><span style="font-family:'Times New Roman', serif">73430</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">667.00</span></p></td></tr><tr><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>73433</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">Next generation sequencing (NGS) test for neurotrophic receptor tyrosine kinase (</span><span style="font-family:'Times New Roman', serif; font-style:italic">NTRK1</span><span style="font-family:'Times New Roman', serif">, </span><span style="font-family:'Times New Roman', serif; font-style:italic">NTRK2</span><span style="font-family:'Times New Roman', serif">, </span><span style="font-family:'Times New Roman', serif; font-style:italic">NTRK3</span><span style="font-family:'Times New Roman', serif">) fusions by RNA or DNA in tumour tissue from a patient with locally advanced or metastatic solid tumour, if:</span></p><p class="Tabletext1" style="margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(a)</span><span style="width:5.79pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">the tumour is at risk of being caused by an </span><span style="font-family:'Times New Roman', serif; font-style:italic">NTRK </span><span style="font-family:'Times New Roman', serif">gene fusion as determined by either:</span></p><p class="Tabletext1" style="margin-left:53.85pt; margin-bottom:0pt; text-indent:-11.3pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(i)</span><span style="width:0.92pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">occurring in a child less than 18 years of age; or</span></p><p class="Tabletext1" style="margin-left:53.85pt; margin-bottom:0pt; text-indent:-11.3pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(ii)</span><span style="width:16.01pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">being mammary analogue secretory carcinoma of the salivary gland; or</span></p><p class="Tabletext1" style="margin-left:53.85pt; margin-bottom:6pt; text-indent:-11.3pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(iii)</span><span style="width:12.96pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">being secretory breast carcinoma;</span></p><p class="Tabletext1" style="margin-left:36pt; margin-bottom:6pt; text-indent:-18pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">(b)</span><span style="width:5.17pt; text-indent:0pt; font-family:'Times New Roman', serif; display:inline-block"> </span><span style="font-family:'Times New Roman', serif">the test is requested by a specialist or consultant physician to determine if requirements relating to </span><span style="font-family:'Times New Roman', serif; font-style:italic">NTRK</span><span style="font-family:'Times New Roman', serif"> gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled</span></p><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">This item cannot be claimed if item</span><span style="font-family:'Times New Roman', serif"> </span><span style="font-family:'Times New Roman', serif">73430 has been claimed for the same patient during the same cancer diagnosis</span></p><p class="Tabletext1" style="margin-bottom:6pt; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">Applicable only once per cancer diagnosis</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">1,000.00</span></p></td></tr><tr><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>73436</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p><span>A test of tumour tissue from a patient with a new diagnosis of non</span><span>‑</span><span>small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:</span></p><p style="margin-top:2pt; margin-left:17.15pt; margin-bottom:6pt; text-indent:-17.15pt; line-height:11.5pt"><span>(a)</span><span style="width:4.94pt; text-indent:0pt; display:inline-block"> </span><span>for MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping alterations (METex14sk) status to determine eligibility for access to a</span><span style="font-style:italic"> </span><span>relevant treatment under the Pharmaceutical Benefits Scheme; and</span></p><p style="margin-top:2pt; margin-left:17.15pt; margin-bottom:6pt; text-indent:-17.15pt; line-height:11.5pt"><span>(b)</span><span style="width:4.32pt; text-indent:0pt; display:inline-block"> </span><span>not associated with a service to which item 73437 or 73438 applies</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">397.35</span></p></td></tr><tr><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73437</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:6pt; line-height:12pt"><span>A nucleic acid</span><span>‑</span><span>based multi</span><span>‑</span><span>gene panel test of tumour tissue from a patient with a new diagnosis of non</span><span>‑</span><span>small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:</span></p><p class="Item" style="margin-left:17.85pt; text-indent:-17.85pt"><span>(a)</span><span style="width:5.64pt; text-indent:0pt; display:inline-block"> </span><span>to detect variants in at least EGFR, BRAF, KRAS and MET exon 14 to determine eligibility for a</span><span style="font-style:italic"> </span><span>relevant treatment under the Pharmaceutical Benefits Scheme; and</span></p><p style="margin-top:4pt; margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(b)</span><span style="width:5.02pt; text-indent:0pt; display:inline-block"> </span><span>to detect the fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 to determine eligibility for a relevant treatment under the PBS; and</span></p><p style="margin-top:4pt; margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(c)</span><span style="width:5.64pt; text-indent:0pt; display:inline-block"> </span><span>not associated with a service to which item 73438, 73439, 73337, 73341, 73344, 73436 or 73351 applies</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">1,247.00</span></p></td></tr><tr><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73438</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:6pt; line-height:12pt"><span>A DNA</span><span>‑</span><span>based multi</span><span>‑</span><span>gene panel test of tumour tissue from a patient with a new diagnosis of non</span><span>‑</span><span>small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:</span></p><p style="margin-top:4pt; margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(a)</span><span style="width:5.64pt; text-indent:0pt; display:inline-block"> </span><span>to detect variants in at least EGFR, BRAF, KRAS and MET exon 14; and</span></p><p style="margin-top:4pt; margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(b)</span><span style="width:5.02pt; text-indent:0pt; display:inline-block"> </span><span>to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and</span></p><p style="margin-top:4pt; margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(c)</span><span style="width:5.64pt; text-indent:0pt; display:inline-block"> </span><span>not associated with a service to which item 73437, 73337, 73436 or 73351 applies</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">682.35</span></p></td></tr><tr><td style="width:15.38%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%"><span>73439</span></p></td><td style="width:64%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:6pt; line-height:12pt"><span>A nucleic acid</span><span>‑</span><span>based multi</span><span>‑</span><span>gene panel test of tumour tissue from a patient with a new diagnosis of non</span><span>‑</span><span>small cell lung cancer and with documented absence of activating variants of the EGFR gene, KRAS, BRAF and MET exon14, requested by, or on behalf of, a specialist or consultant physician, if the test is:</span></p><p style="margin-top:4pt; margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(a)</span><span style="width:5.64pt; text-indent:0pt; display:inline-block"> </span><span>for fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3 to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and</span></p><p style="margin-top:4pt; margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(b)</span><span style="width:5.02pt; text-indent:0pt; display:inline-block"> </span><span>not associated with a service to which item 73437, 73341, 73344 or 73351 applies</span></p></td><td style="width:20.62%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="Tabletext1" style="margin-bottom:6pt; text-align:right; line-height:115%; font-size:11pt"><span style="font-family:'Times New Roman', serif">682.35</span></p></td></tr></tbody></table>